专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011156252A3 SULFATION OF WNT PATHWAY PROTEINS 审中-公开
标题翻译： WNT途径蛋白质的硫化
公开(公告)号：WO2011156252A3
公开(公告)日：2012-02-02
申请号：PCT/US2011039223
申请日：2011-06-06
申请人： ENZO BIOCHEM INC , RABBANI JOSHUA , DONEGAN JAMES J
发明人： RABBANI JOSHUA , DONEGAN JAMES J
IPC分类号： C07K14/51 , C07K14/47 , C07K14/705 , C07K14/71 , C07K16/18 , C07K16/22 , C07K16/28
CPC分类号： C07K16/22 , C07K14/47 , C07K14/51 , C07K14/705 , C07K14/71 , C07K2317/54 , C07K2317/55 , C07K2317/76
摘要： Provided is a protein comprising an antibody binding site that binds to a sulfated epitope of a Wnt pathway protein that is not Wnt5A, Wnt11, or Wnt3a. Also provided is a composition comprising an isolated, and purified Wnt pathway protein, where the protein is sulfated but not glycosylated. Additionally provided is a preparation of a Wnt pathway protein comprising at least one sulfation site and at least one glycosylation site, where all of the Wnt pathway protein in the preparation is glycosylated but not sulfated. Further provided is a composition comprising a peptide less than 75 amino acids or amino acid analogs, the peptide consisting of a fragment of a Wnt pathway protein, wherein the fragment is sulfated. A modified Wnt pathway protein comprising a sulfation site that, is not present, in the native Wnt pathway protein is also provided. Also provided is a method of detecting or quantifying a sulfated Wnt pathway protein in a preparation. Additionally, a modified Wnt pathway protein, lacking a sulfation site that, is present in the native Wnt pathway protein is provided. Also provided, is methods of treating a subject having a disease exacerbated by Wnt activation. Additionally, a method of treating a subject having a disease exacerbated by Wnt inhibition is provided.
摘要翻译：提供了包含结合不是Wnt5A，Wnt11或Wnt3a的Wnt途径蛋白的硫酸化表位的抗体结合位点的蛋白质。还提供了包含分离的和纯化的Wnt途径蛋白质的组合物，其中蛋白质被硫酸化但不被糖基化。另外提供了包含至少一个硫酸化位点和至少一个糖基化位点的Wnt途径蛋白质的制剂，其中所述制剂中的所有Wnt途径蛋白质被糖基化但不硫酸化。还提供了包含小于75个氨基酸或氨基酸类似物的肽的组合物，所述肽由Wnt途径蛋白质的片段组成，其中所述片段被硫酸化。还提供了包含未存在于天然Wnt途径蛋白中的硫酸化位点的修饰的Wnt途径蛋白。还提供了在制剂中检测或定量硫酸化Wnt途径蛋白的方法。另外，提供了在天然Wnt途径蛋白中存在缺乏硫酸化位点的修饰的Wnt途径蛋白。还提供了治疗患有由Wnt活化加重的疾病的受试者的方法。另外，提供了治疗由Wnt抑制加剧的疾病的受试者的方法。

2. 发明申请

WO2010017472A1 COMPOSITIONS AND METHODS AFFECTING THE SIGNALING PATHWAYS OF LRP RECEPTORS 审中-公开
标题翻译：影响LRP受体信号通路的组成和方法
公开(公告)号：WO2010017472A1
公开(公告)日：2010-02-11
申请号：PCT/US2009/053146
申请日：2009-08-07
申请人： ENZO BIOCHEM, INC. , RABBANI, Elazar , LI, Xiaofeng , LIU, Dakai , ZHANG, Yazhou , JIN, Richard , BHATTACHARYYA, Riddhi , CHENG, Wei , ZHANG, Guangrong , LIANG, Yuanxing , ENEA, Vincenzo , DONEGAN, James, J.
发明人： RABBANI, Elazar , LI, Xiaofeng , LIU, Dakai , ZHANG, Yazhou , JIN, Richard , BHATTACHARYYA, Riddhi , CHENG, Wei , ZHANG, Guangrong , LIANG, Yuanxing , ENEA, Vincenzo , DONEGAN, James, J.
IPC分类号： G01N33/53
CPC分类号： A61K31/538 , A61K31/015 , A61K31/185 , A61K31/192 , A61K31/235 , A61K31/395 , A61K31/535 , A61K38/00 , G01N33/5011 , G01N33/5041 , G01N33/564 , G01N33/92 , G01N2333/705 , G01N2800/24
摘要： The present invention relates to the field of therapeutic methods, compositions and uses thereof, that affect, directly or indirectly, the behavior of LRP receptors. These compositions and methods result in the treatment of inflammatory, immunological and metabolic conditions. More particularly, the methods and compositions of the invention are directed to the identification of small molecules, drugs and/or pharmacological agents that affect the Wnt pathway by affecting normal complex formation among various signaling receptors, the LRP5 and LRP6 receptor, and related ligands.
摘要翻译：本发明涉及直接或间接影响LRP受体的行为的治疗方法，组合物和用途领域。这些组合物和方法导致治疗炎症，免疫和代谢疾病。更具体地，本发明的方法和组合物涉及通过影响各种信号传导受体（LRP5和LRP6受体）和相关配体之间的正常复合物形成来鉴定影响Wnt途径的小分子，药物和/或药理学试剂。

3. 发明申请

WO2018237379A3 SPHINGOSINE PATHWAY MODULATING COMPOUNDS FOR THE TREATMENT OF CANCERS 审中-公开
公开(公告)号：WO2018237379A3
公开(公告)日：2018-12-27
申请号：PCT/US2018/039263
申请日：2018-06-25
申请人： ENZO BIOCHEM, INC. , ELAZAR, Rabbani , DONEGAN, James, J. , DIAMOND, Paul
发明人： ELAZAR, Rabbani , DONEGAN, James, J. , DIAMOND, Paul
IPC分类号： A61K31/135 , A61K31/4245 , A61K45/06 , A61P35/00 , A61P35/02
摘要： The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine- 1 -phosphate receptor agonists, such as ozanimod.

4. 发明申请

WO2014176555A3 IMMUNE MODULATION FOR TREATMENT OF AUTOIMMUNE DISEASE 审中-公开
公开(公告)号：WO2014176555A3
公开(公告)日：2014-10-30
申请号：PCT/US2014/035549
申请日：2014-04-25
申请人： ENZO BIOCHEM, INC. , NUSSENBLATT, Richard , LIU, Baoying , WEI, Lai , RABBANI, Elazar , DONEGAN, James, J.
发明人： NUSSENBLATT, Richard , LIU, Baoying , WEI, Lai , RABBANI, Elazar , DONEGAN, James, J.
IPC分类号： A61K39/00 , A61K39/38 , C40B30/04 , G01N33/00
摘要： The disclosure relates to methods of identifying a compound that comprises an epitope that induces immune tolerance in a patient suffering from an autoimmune disease. The disclosure further relates to methods of treating an autoimmune disease by administering (i) a compound identified by the methods described herein, (ii) regulatory T-cells from the patient or a compatible donor, or (iii) a combination of regulatory T-cells and a compound identified by the methods described herein. The disclosure further relates to methods of treating age- related macular degeneration and uveitis. The disclosure also relates to methods of monitoring, diagnosing and/or prognosticating an autoimmune disease in a patient.

5. 发明申请

WO2014176235A3 TOLERIZING TREATMENTS FOR AUTOIMMUNE DISEASE 审中-公开
公开(公告)号：WO2014176235A3
公开(公告)日：2014-10-30
申请号：PCT/US2014/034948
申请日：2014-04-22
申请人： ENZO BIOCHEM, INC. , NUSSENBLATT, Richard , LIU, Baoying , WEI, Lai , RABBANI, Elazar , DONEGAN, James, J.
发明人： NUSSENBLATT, Richard , LIU, Baoying , WEI, Lai , RABBANI, Elazar , DONEGAN, James, J.
IPC分类号： A61K39/00 , A61K39/38 , C40B30/04 , G01N33/00
摘要： The disclosure relates to methods of identifying a compound that comprises an epitope that induces immune tolerance in a patient suffering from an autoimmune disease. The disclosure further relates to methods of treating an autoimmune disease by administering (i) a compound identified by the methods described herein, (ii) regulatory T-cells from the patient or a compatible donor, or (iii) a combination of regulatory T-cells and a compound identified by the methods described herein. The disclosure further relates to methods of treating age-related macular degeneration and uveitis.

6. 发明申请

WO2013003178A1 SULFATION OF WNT PATHWAY PROTEINS 审中-公开
标题翻译： WNT途径蛋白的硫化
公开(公告)号：WO2013003178A1
公开(公告)日：2013-01-03
申请号：PCT/US2012/043451
申请日：2012-06-21
申请人： ENZO BIOCHEM, INC. , RABBANI, Joshua , DONEGAN, James J. , LI, Xiaofeng
发明人： RABBANI, Joshua , DONEGAN, James J. , LI, Xiaofeng
IPC分类号： C07K14/51 , C07K7/04
CPC分类号： A61K38/1709 , A61K38/08 , A61K38/10 , C07K14/47 , C07K14/51 , C07K14/705 , C07K14/71
摘要： Provided is a composition comprising a peptide comprising amino acids and/or amino acid analogs comprising a continuous sequence of a sclerostin fragment comprising Tyr43 or Tyr213. Also provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being sulfated, where the composition is capable of inhibiting sclerostin binding to an LRP. Further provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being post-translationally sulfated, where the composition is capable of inhibiting binding of a protein ligand comprising a sulfation site to its binding partner. Additionally provided is a method of enhancing a Wnt signaling pathway comprising contacting an LRP5/6 receptor in the Wnt signaling pathway with either of the above-described compositions that comprise a sequence of a sclerostin fragment or is capable of inhibiting sclerostin binding to an LRP, where the tyrosine or tyrosine analog is not sulfated, in a manner sufficient to enhance the Wnt signaling pathway. Further provided is a method of treating a subject having a disease exacerbated by inhibition of a Wnt signaling pathway comprising administering either of the above-described compositions that comprise a sequence of a sclerostin fragment or is capable of inhibiting sclerostin binding to an LRP, where the tyrosine or tyrosine analog is not sulfated, to the subject in a manner sufficient to reduce the inhibition of the Wnt signaling pathway. Also, a method of inhibiting binding of a protein ligand comprising a sulfation site to its binding partner is provided. The method comprises adding the above-described composition that is capable of inhibiting binding of a protein ligand to its binding partner to the protein ligand and its binding partner in a manner sufficient to inhibit binding of the protein ligand to its binding partner.
摘要翻译：提供了包含包含氨基酸和/或氨基酸类似物的肽的组合物，其包含包含Tyr43或Tyr213的硬化蛋白片段的连续序列。还提供了包含包含少于约75个氨基酸和/或氨基酸类似物的肽的组合物，其包含能够被硫酸化的氨基酸或氨基酸类似物，其中该组合物能够抑制与LRP结合的硬皮蛋白。还提供了一种组合物，其包含包含小于约75个氨基酸和/或氨基酸类似物的肽，其包含能够翻译后硫酸化的氨基酸或氨基酸类似物，其中组合物能够抑制蛋白质配体的结合，所述蛋白质配体包含硫酸化位点到其结合配偶体。另外提供了增强Wnt信号传导途径的方法，包括使Wnt信号传导途径中的LRP5 / 6受体与包含硬化蛋白片段序列的任一上述组合物接触或能够抑制硬化蛋白酶与LRP结合，其中酪氨酸或酪氨酸类似物不被硫酸化，以足以增强Wnt信号通路的方式。还提供了一种治疗具有通过抑制Wnt信号传导途径加重疾病的受试者的方法，包括施用包含硬化蛋白酶片段序列的上述组合物或能够抑制硬化蛋白与LRP的结合，其中酪氨酸或酪氨酸类似物不以足以降低Wnt信号传导途径抑制的方式硫酸化。此外，提供了抑制包含硫酸化位点的蛋白质配体与其结合配偶体的结合的方法。该方法包括加入能够以足以抑制蛋白质配体与其结合配偶体的结合的方式将蛋白质配体与其结合配偶体结合至蛋白质配体及其结合配偶体的上述组合物。

7. 发明申请

WO2016105605A1 COMPREHENSIVE AND COMPARATIVE FLOW CYTOMETRY-BASED METHODS FOR IDENTIFYING THE STATE OF A BIOLOGICAL SYSTEM 审中-公开
标题翻译：用于识别生物系统状态的综合和比较流式细胞仪检测方法
公开(公告)号：WO2016105605A1
公开(公告)日：2016-06-30
申请号：PCT/US2015/046912
申请日：2015-08-26
申请人： ENZO BIOCHEM, INC. , RABBANI, Elazar , DONEGAN, James, J. , L'HULLIER, Andrew, Stewart
发明人： RABBANI, Elazar , DONEGAN, James, J. , L'HULLIER, Andrew, Stewart
IPC分类号： C12Q1/68 , C12Q1/70
CPC分类号： C12Q1/6886 , C12Q1/6841 , C12Q1/708 , G01N33/505 , C12Q2525/301 , C12Q2545/101 , C12Q2545/113 , C12Q2565/101 , C12Q2565/1015 , C12Q2565/107 , C12Q2565/626
摘要： The present disclosure provides comprehensive and comparative flow cytometry-based methods for identifying the state of a biological system by identifying the phenotype of cells and correlating the phenotype with the gene expression profile of the cells, which is indicative of cell function. The cells can be immune cells from a subject suffering from immune -mediated disorders that result in imbalance of the immune system and impair a subject's ability to recognize self-antigens or fight infection or disease. In certain aspects, cell phenotype is identified by detecting and/or quantifying one or more markers on the cell surface or intracellularly, which readily enables identification of specific sub-types of cells of interest, which can then be analyzed for gene expression in order to assay cell function. In additional aspects, function of particular subsets of cells identified by cell surface markers is determined by detecting patterns of gene expression, expression of RNA or other markers, by detecting and/or quantifying transcription in the cell, by assaying DNA content, by assaying cell receptors, and/or by detecting the number and/or state of cellular organelles, receptors and/or transport systems.
摘要翻译：本公开提供了通过鉴定细胞表型并将表型与细胞的基因表达谱相关联来鉴定生物系统的状态的综合和比较的流式细胞术方法，其指示细胞功能。细胞可以是来自患有免疫介导的障碍的受试者的免疫细胞，其导致免疫系统的不平衡并且损害受试者识别自身抗原或抵抗感染或疾病的能力。在某些方面，通过检测和/或定量细胞表面或细胞内的一种或多种标志物来鉴定细胞表型，其可以容易地鉴定感兴趣的细胞的特定亚型，然后可以分析它们的基因表达，以便测定细胞功能。在另外的方面，通过检测基因表达，RNA或其他标志物的表达，通过检测和/或定量细胞中的转录，通过测定细胞DNA来测定DNA含量来确定特定细胞表面标记子集的功能和/或通过检测细胞器细胞器，受体和/或转运系统的数量和/或状态。

8. 发明申请

WO2014176235A2 TOLERIZING TREATMENTS FOR AUTOIMMUNE DISEASE 审中-公开
标题翻译：治疗自身免疫疾病的治疗
公开(公告)号：WO2014176235A2
公开(公告)日：2014-10-30
申请号：PCT/US2014034948
申请日：2014-04-22
申请人： ENZO BIOCHEM INC , NUSSENBLATT RICHARD , LIU BAOYING , WEI LAI , RABBANI ELAZAR , DONEGAN JAMES J
发明人： NUSSENBLATT RICHARD , LIU BAOYING , WEI LAI , RABBANI ELAZAR , DONEGAN JAMES J
IPC分类号： A61K35/14 , G01N33/50
CPC分类号： A61K35/17 , C12N5/0636 , C12N2501/998 , G01N33/505
摘要： The disclosure relates to methods of identifying a compound that comprises an epitope that induces immune tolerance in a patient suffering from an autoimmune disease. The disclosure further relates to methods of treating an autoimmune disease by administering (i) a compound identified by the methods described herein, (ii) regulatory T-cells from the patient or a compatible donor, or (iii) a combination of regulatory T-cells and a compound identified by the methods described herein. The disclosure further relates to methods of treating age-related macular degeneration and uveitis.
摘要翻译：本公开涉及鉴定包含在患有自身免疫疾病的患者中诱导免疫耐受的表位的化合物的方法。本公开还涉及通过施用（i）通过本文所述的方法鉴定的化合物，（ii）来自患者或相容供体的调节性T细胞，或（iii）调节性T细胞的组合来治疗自身免疫性疾病的方法，细胞和通过本文所述方法鉴定的化合物。本发明还涉及治疗年龄相关性黄斑变性和葡萄膜炎的方法。

9. 发明申请

WO2012064501A1 HYDROXYCHOLESTEROL IMMUNOASSAY 审中-公开
标题翻译：羟吗啉酮免疫
公开(公告)号：WO2012064501A1
公开(公告)日：2012-05-18
申请号：PCT/US2011/057664
申请日：2011-10-25
申请人： ENZO BIOCHEM, INC. , MULLENIX, Michael, C. , ZIPKIN, Robert, Elliot , ADAMS, Jeffrey, Kroll , PATTON, Wayne, Forrest , DONEGAN, James, J.
发明人： MULLENIX, Michael, C. , ZIPKIN, Robert, Elliot , ADAMS, Jeffrey, Kroll , PATTON, Wayne, Forrest , DONEGAN, James, J.
IPC分类号： C07K16/44 , C07J9/00 , G01N33/569
CPC分类号： G01N33/92 , C07J9/00 , C07J43/003 , C07K16/18 , C07K16/44 , C07K2317/21 , G01N33/5308 , G01N33/56966 , G01N2800/2835 , G01N2800/285 , G01N2800/52
摘要： Provided is a deri vative of 22-hydroxyeholesterol, 24S-hydroxychoIesterol, 25- hydroxycholesierol, 26-hydroxyeh.oles.erol or 27-hydroxyeholesierol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol 24S-hydroxyeholesterol, 25-hydroxycholesterol l 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol,.24S-hydroxycholesterol, 25-hydrox.ycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol. 24S-hydroxycholesterol 25-hydroxycholesterol 26- hydroxycholesterol or 27-hydroxycholesterol A method of detecting an enzyme or enzymes utilized in phase II drug metabolism is also provided. Also, a method of detecting an enzyme that synthesizes 22-hydroxycholesterol 245-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Further provided is a method of evaluating progression of multiple sclerosis in a patient Also provided is a method of determining whether a treatment for multiple sclerosis in a patient is effective. Further, a method, of evaluating progression of Huntington's disease in a patient is provided. Additionally provided is a method ofdetemiining whether a treatment for Huntington's disease in a patient is effective.
摘要翻译：提供的是22-羟基胆固醇，24S-羟基胆甾醇，25-羟基胆甾烯醇，26-羟基甜菜碱或27-羟基胆甾醇的衍生物。还提供了与上述衍生物结合的蛋白质。还提供了包含特异性结合22-羟基胆固醇24 S-羟基胆固醇，25-羟基胆固醇l26-羟基胆固醇或27-羟基胆固醇的抗体的抗体组合物。此外，提供了制备特异性结合22-羟基胆固醇，24S-羟基胆固醇，25-羟基胆固醇26-羟基胆固醇或27-羟基胆固醇的抗体的方法。此外，提供了测定22-羟基胆固醇，.24S-羟基胆固醇，25-羟基胆固醇，26-羟基胆固醇或27-羟基胆固醇的方法。另外提供了用于检测22-羟基胆固醇的试剂盒。 24S-羟基胆固醇25-羟基胆固醇26-羟基胆固醇或27-羟基胆固醇还提供了检测在II期药物代谢中使用的酶或酶的方法。此外，提供了检测合成22-羟基胆固醇245-羟基胆固醇，25-羟基胆固醇，26-羟基胆固醇或27-羟基胆固醇的酶的方法。进一步提供评估患者多发性硬化的进展的方法还提供了确定患者多发性硬化症的治疗是否有效的方法。此外，提供了评价患者中亨廷顿病进展的方法。另外提供了一种测定患者中亨廷顿氏病的治疗是否有效的方法。

10. 发明申请

WO2010028349A3 FLUOROCHROMES FOR ORGANELLE TRACING AND MULTI-COLOR IMAGING 审中-公开
公开(公告)号：WO2010028349A3
公开(公告)日：2010-03-11
申请号：PCT/US2009/056198
申请日：2009-09-08
申请人： ENZO LIFE SCIENCES, INC. , PATTON, Wayne, Forrest , PANDE, Praveen , XIANG, Yuejun , LI, Zaiguo , DONEGAN, James, J. , RABBANI, Elazar
发明人： PATTON, Wayne, Forrest , PANDE, Praveen , XIANG, Yuejun , LI, Zaiguo , DONEGAN, James, J. , RABBANI, Elazar
IPC分类号： C09K19/60 , C09B1/20 , C09B1/54
摘要： Provided are compounds, methods and kits for identifying in cells of interest organelles including nuclei and a wide variety of organelles other than nuclei (non-nuclear organelles), as well as cell regions or cell domains. These compounds and methods can be used with other conventional detection reagents for identifying the location or position or quantity of organelles and even for distinguishing between organelles in cells of interest.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式